Amicus Therapeutics, Shire deal
The companies mutually ended a 2007 deal to develop Amicus' Amigal migalastat, Plicera afegostat tartrate and AT2220 deoxynojirimycin. Amicus regains all rights to the compounds and will receive a final $5.2 million payment from the deal this quarter. A Shire spokesperson said the programs have "experienced some outcomes that delayed their development," and therefore Shire concluded that the risk profile no longer fit the company's criteria.
Amicus will continue development of Amigal, which is in Phase III testing to treat Fabry's disease. Data for the small molecule that enhances alpha galactosidase A activity are expected mid-2011. In October, Amicus said it did not expect to advance Plicera into Phase III testing to treat Type I Gaucher's disease. Plicera is an orally available, small molecule chaperone that binds to glucocerebrosidase. AT2220 is in Phase I testing to treat Pompe's disease. Data for the chaperone that binds to acid alpha glucosidase (GAA) are expected next half. ...